3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
11
Phase 2
8
Phase 3
3
Phase NA
2
Phase 2/3
2
Phase 4
1
Phase 1/2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
2
Tumor-Agnostic
1
Conditions
Melanoma
8
Neoplasms
3
Skin Neoplasms
1
Skin Diseases
1
Neoplasm Metastasis
1
Colorectal Cancer Metastatic
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Vemurafenib
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA
NCT01597908
2021-02-24
COMBI-v
Novartis
Phase 3
Completed
704 enrolled
13 charts